Scholarlink

Background <p>This study aimed to determine whether clinical treatment score post-5&#xa0;years (CTS5) could predict the clinical benefits of extended endocrine therapy (ExET) in young and old patients.</p> Methods <p>We reviewed 2495 hormone receptor-positive breast cancer patients treated between 2001 and 2012 who were free from recurrence or death during the 5&#xa0;years post-surgery in South Korea. The cohort was analyzed separately based on age (≤ 50&#xa0;years and &gt; 50&#xa0;years). Multivariable analysis was conducted, and a cutoff of CTS5 &lt; 3.13 was defined as the low group and CTS5 ≥ 3.13 as the intermediate/high (int/high) group.</p> Results <p>The median follow-up duration was 115&#xa0;months. Regardless of young and old age at diagnosis, the low group displayed considerably enhanced disease-free survival. Multivariate analysis revealed that the low group emerged as an independent and favorable prognostic factor for disease-free survival after adjusting for ExET use and prognostic parameters. Patients in the low group demonstrated a trend toward improved overall survival compared to those in the int/high group, reaching marginal statistical significance. ExET use demonstrated a significant correlation with improved disease-free survival, particularly in patients aged ≤ 50&#xa0;years.</p> Conclusions <p>ExET should be considered in premenopausal and postmenopausal breast cancer patients with high CTS5 levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical treatment score post-5 years and survival benefit from extended endocrine therapy for breast cancer patients under and over 50 years of age

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月17日

查看全文
  • Jee Hyun Ahn,
  • Suk Jun Lee,
  • Seung Hye Yang,
  • Jee Ye Kim,
  • Hyung Seok Park,
  • Seung Il Kim,
  • Byeong-Woo Park,
  • Seho Park

摘要

Background

This study aimed to determine whether clinical treatment score post-5 years (CTS5) could predict the clinical benefits of extended endocrine therapy (ExET) in young and old patients.

Methods

We reviewed 2495 hormone receptor-positive breast cancer patients treated between 2001 and 2012 who were free from recurrence or death during the 5 years post-surgery in South Korea. The cohort was analyzed separately based on age (≤ 50 years and > 50 years). Multivariable analysis was conducted, and a cutoff of CTS5 < 3.13 was defined as the low group and CTS5 ≥ 3.13 as the intermediate/high (int/high) group.

Results

The median follow-up duration was 115 months. Regardless of young and old age at diagnosis, the low group displayed considerably enhanced disease-free survival. Multivariate analysis revealed that the low group emerged as an independent and favorable prognostic factor for disease-free survival after adjusting for ExET use and prognostic parameters. Patients in the low group demonstrated a trend toward improved overall survival compared to those in the int/high group, reaching marginal statistical significance. ExET use demonstrated a significant correlation with improved disease-free survival, particularly in patients aged ≤ 50 years.

Conclusions

ExET should be considered in premenopausal and postmenopausal breast cancer patients with high CTS5 levels.